We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App

Nano-Based Sensor Technologies Could Make It Possible to Detect COVID-19 at Any Disease Stage, Say Researchers

By LabMedica International staff writers
Posted on 02 Dec 2020
Print article
Image: Various diagnostic techniques can be used for sensing the RNA of SARS-CoV-2 (Photo courtesy of Saadet Alpdagtas and Elif Ilhan)
Image: Various diagnostic techniques can be used for sensing the RNA of SARS-CoV-2 (Photo courtesy of Saadet Alpdagtas and Elif Ilhan)
Despite various diagnostic techniques for COVID-19, no single test is available for the entire stage of the disease, although nano-based sensor technologies could make it possible to detect the attack at any stage of the disease, according to researchers.

Researchers at the Van Yuzuncu Yil University (Van, Turkey) along with their colleagues evaluated the available diagnostic techniques for COVID-19 and determined the key steps required for better testing moving forward. Laboratory tests that target the virus's genes - known as real-time reverse transcription-polymerase chain reaction assays - are currently the gold standard for testing. But according to the US Food and Drug Administration (FDA), these tests could give false negatives. These tests depend on the presence of antibodies, which may not have yet been developed in the early stages of infection. Since different antibodies appear at different stages, diagnostic tests must be chosen to target the appropriate immune response based on when an individual is believed to have been infected.

"There is not any available single test for the entire stage of the disease," said Oguzhan Gunduz, one of the researchers. "However, I think it may be possible to detect the attack at any stage of the disease with nano-based sensor technologies."

The researchers have emphasized point-of-care testing as an urgent objective. These types of tests would help detect the virus on site without the need for laboratory equipment or specialized personnel, eliminating or reducing the wait time between testing and obtaining results

"A quite sensitive test that can measure the existent tiny number of viral particles, or any parameter related to the particle - weight, structure, charge, diameter - can provide rapid and early diagnosis," said Gunduz.

When asked about the potential for a more comfortable testing method, Gunduz stressed that this depends on the sampling method and its sensitivity. A fingertip blood test or a saliva test could potentially be underway, though these have their own drawbacks.

"There are such tests, but they come up with accuracy and specificity issues," added Gunduz.

Related Links:
Van Yuzuncu Yil University

Print article


Molecular Diagnostics

view channel
Image: FIT (Fecal Immunochemical Test) is a stool test designed to identify possible signs of bowel disease. It detects minute amounts of blood in feces (fecal occult blood) (Photo courtesy of Alpha Laboratories, United Kingdom)

Study Confirms Performance of Rapid Stool Test for Detection of Colorectal Cancer

A recently published paper confirmed the diagnostic performance of the fecal immunochemical test (FIT) for patients with low-risk symptoms of colorectal cancer. The FIT uses specific antibodies to detect... Read more


view channel
Image: The Leica Bond III stainer is fully automated Immunohistochemical and In Situ Hybridization (IHC and ISH stainer) (Photo courtesy of Leica Biosystems).

Mismatch Repair/Microsatellite Instability Evaluated Using Cytology Effusion Specimens

DNA mismatch repair (MMR) status is routinely assessed in colorectal and endometrial carcinoma as a method of cancer prevention, surveillance in patients with Lynch syndrome and their families, and for... Read more


view channel

Roche Renews Partnership with Sysmex to Deliver Hematology Testing Solutions

Under the new framework of a Global Business Partnership Agreement (GBP) signed between Roche (Basel, Switzerland) and Sysmex Corporation (Kobe, Japan), both the companies have renewed their commitment... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.